Vitrakvi

Vitrakvi (larotrectinib) is an oral therapy used for treating solid tumors with NTRK gene fusions. This prescription medicine targets specific genetic changes linked to certain cancers. Always consult a healthcare provider for suitability.

Vitrakvi is prescribed for adults and children with solid tumors that have an NTRK gene fusion. It is used when the cancer has spread or cannot be surgically removed. This medication targets the genetic cause of the tumor, not its location in the body. It may be used for various cancer types, including lung, thyroid, and salivary gland cancers.

Vitrakvi works by blocking signals that cause cancer cells to grow and divide. Patients may experience changes in how they feel while taking this medicine, such as reduced symptoms related to their condition. Individual responses can vary, and effects are typically monitored by a healthcare professional.

Keep Vitrakvi in its original packaging and store at room temperature away from moisture and heat. Always handle with care and keep out of reach of children and pets. Report any unusual symptoms or side effects to your doctor promptly. Do not alter your dose without medical advice.

Vitrakvi may interact with strong CYP3A inhibitors or inducers, which can affect how the medicine works. Grapefruit products and certain supplements may also interact. Always inform your healthcare provider about all medications and supplements you are taking. Alcohol use should be discussed with a doctor.